• The modern marketing maze

    Marketing in our industry is not for the faint-hearted, although it is an area where dynamic teams can discover communicative muscles they never knew they had. As digital possibilities emerge at pace, the modern marketing maze offers exciting opportunities, but identifying them amid regulation and digital domination presents a formidable set of challenges. Challenges which, curiously, many relish...

  • Pharmaceutical pricing - it’s political

    Dr Joe Zammit-Lucia on why it is becoming increasingly import for pharma companies to develop new approaches to pricing that have political resonance

  • The Plan in action

    Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the seismic changes that have been occurring in the NHS since the Long Term Plan was published

News

View all
Thumbnail image for Bayer wins FDA approval for Gadavist

Bayer wins FDA approval for Gadavist

CAD is the most common type of heart disease in the United States, as up to one half of middle aged men and one third of middle aged women in the US are at risk of developing CAD during their lifetime.

16th July 2019

Web Exclusives

View all
Thumbnail image for Pharma has a case of innovation fatigue - here's how to treat it

Pharma has a case of innovation fatigue - here's how to treat it

The pharma innovation story isn’t resonating with vital stakeholders: prescribers and payers working in healthcare settings. Data from a global study which surveyed decision-makers in the healthcare sector reveals that only 39% of respondents in the UK saw the pharmaceutical industry as innovative.

Thumbnail image for Narrowing the provision

Narrowing the provision

The Court of Justice of the European Union (CJEU) has dealt a blow to innovators in two recent significant judgments, addressing questions posed by national courts struggling to judge the eligibility of SPC applications.

Thumbnail image for SmartPeople: James Merson

SmartPeople: James Merson

James Merson, global therapeutic area head for Infectious Diseases at Janssen Research & Development, believes that through continued advancements in science “we can change the trajectory of health for humanity and strive to make infectious diseases an issue of the past”

Thumbnail image for Company Focus: MedPharm

Company Focus: MedPharm

Jeremy Drummond, senior vice president of Business Development at MedPharm, on the challenges and opportunities of topical delivery

Thumbnail image for Connected labelling  - the final frontier?

Connected labelling - the final frontier?

However much progress life sciences companies have made in bringing their regulatory information under control, labelling management continues to overshadow these accomplishments. Too often labelling is disconnected from other systems, forcing heavy reliance on manual processes and checks which in turn can cause hold-ups and create an undesirable source of risk, especially across country borders. Agnes Cwienczek delves deeper into the issues and potential remedies

Thumbnail image for The modern marketing maze

The modern marketing maze

Marketing in our industry is not for the faint-hearted, although it is an area where dynamic teams can discover communicative muscles they never knew they had. As digital possibilities emerge at pace, the modern marketing maze offers exciting opportunities, but identifying them amid regulation and digital domination presents a formidable set of challenges. Challenges which, curiously, many relish...

Thumbnail image for The promised land?

The promised land?

Brexit was supposed to be an opportunity for the UK to strike trade deals outside the EU, but the going is tough

Thumbnail image for A true partnership

A true partnership

Michael Goetzl says it’s time for industry to work in true partnership with health systems “at every step of the way” to speed up access to innovation

Thought Leadership

View all
Thumbnail image for Orphans are not alone

Orphans are not alone

As many as 500 million patients worldwide are suffering from a ‘rare’ disease. This evolving landscape is a growing concern for payers, say Adelphi Values | PROVE

Thumbnail image for Radical Re-Orgs

Radical Re-Orgs

Future commercial models will see radical reorganisation in the coming years

Thumbnail image for Hidden gems

Hidden gems

How can big pharma and SME pharma work to mutual advantage and help patients with unmet medical need?

Webinars

View all

Designing Pharma organisations for success

Across all industries, people are changing the ways they engage with products, services, and brands. View more...

Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download